Navigation Links
22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

This Symposium, organised jointly by the European Organisation for the Research and Treatment of Cancer, the US National Cancer Institute and the American Association for Cancer Research, offers the media:

  • Cutting edge information on new cancer drug research and development from experts in Europe, North America, Asia and Australia;
  • Free registration for bona fide media with official press credentials (press card and/or a commissioning letter on headed paper from the editor of the journal/website they represent);
  • All sessions open to journalists;
  • Media centre with free computing, international phones, and internet.

Around 2,200 international experts in cancer research will present and discuss recent advances in the early development of promising new compounds in different stages of pre-clinical and clinical research.

We welcome the media to the Symposium. Copies of the credentials and identification will be requested at the time of registration and when journalists arrive at the Symposium. Business cards are NOT acceptable.

NB: the official language of the symposium is English and all press materials will be in English.

For media registration, a media registration form can be downloaded at:

Please email it to:
Tel: +32 2 775 02 05
Fax: +32 2 775 02 00

More information on the programme and hotel accommodation is available on the EORTC-NCI-AACR symposium website at:


The Estrel Hotel is the official hotel for EORTC-NCI-AACR 2010.

You are encouraged to book on-line via the Symposium website: or complete the hotel reservation form found in the Symposium programme at and return it by fax, email or post to the following address:

Estrel Hotel and Convention Centre
Sonnenallee 225
12057 Berlin - Germany
Tel: +49 (0)30 6831 0
Fax: +49 (0)30 6831 2345

Reservations are made on a first-come, first-served basis and participants are advised to book early.


Contact: Emma Mason
ECCO-the European CanCer Organisation

Related biology news :

1. Stem Cells and International Stem Cell Symposium present annual stem cells award
2. Military medicine symposium to explore regenerative medicine, behavioral health
3. Sutherland and Berglass to keynote USU-HJF Military Medicine Symposium
4. University at Buffalo symposium on in silico methods, high throughput screening
5. American Chemical Society, Council for Chemical Research to hold R&D symposium Aug. 22
6. Ecologists to discuss impacts of mountaintop mining at special ESA symposium
7. Symposium to explore broadening partnerships to spur medical advances for war injuries
8. American Chemical Society symposium on Deepwater Horizon oil spill on Aug. 24
9. Flowers do it, trees do it: Symposium on plant reproduction
10. IRSF lauds record turn-out for annual Rett Syndrome Symposium
11. Announcing the 1st IOF-ESCEO Pre-Clinical Symposium
Post Your Comments:
(Date:5/12/2016)... , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
Breaking Biology Technology: